• Resiniferatoxin (RTX): Precision Analgesia in TRPV1 Research

  2026-05-23

  Resiniferatoxin (RTX) offers ultra-potent, long-lasting TRPV1 targeting for advanced pain and inflammation models, outperforming traditional agents like capsaicin. Its selective chemical inactivation of sensory neurons enables reproducible, translational workflows in neuropathic and osteoarthritis pain research.

• Technical Guide to Angiotensin I/II (1-5) in RAS Research

  2026-05-22

  Angiotensin I/II (1-5) (Asp-Arg-Val-Tyr-Ile) provides a defined peptide fragment for precise modeling of the renin-angiotensin system in cardiovascular and renal research workflows. It is not suitable for unrelated peptide signaling studies due to its specific biochemical properties and solubility requirements.

• HAUS1 as a Prognostic Biomarker and Immune Modulator in HCC

  2026-05-22

  The referenced study systematically investigates HAUS1 expression in hepatocellular carcinoma (HCC) and elucidates its association with prognosis, immune microenvironment, and cell proliferation. By integrating bioinformatics and functional assays, the work highlights HAUS1 as a promising diagnostic and therapeutic target with direct relevance for future biomarker-driven cancer research.

• Unlocking mRNA Therapeutic Potential: 5-Methyl-CTP as a Stra

  2026-05-21

  This article delivers a thought-leadership perspective for translational researchers, focusing on how 5-Methyl-CTP from APExBIO mechanistically and strategically advances mRNA stability, translation efficiency, and personalized vaccine development. Integrating mechanistic rationale, experimental findings, protocol guidance, and comparative insights, it positions 5-Methyl-CTP as a pivotal tool in the evolving landscape of mRNA drug development, with a special emphasis on next-generation delivery platforms and future clinical translation.

• WWP2-Driven DDX3X Ubiquitination in Diabetic Endothelial Inj

  2026-05-21

  You et al. provide mechanistic insight into how downregulation of WWP2 exacerbates vascular endothelial injury in type 2 diabetes by modulating DDX3X degradation through ubiquitin-proteasome pathways. This work identifies the JNK–WWP2–DDX3X axis as a crucial regulator of endothelial integrity, offering new molecular targets for diabetic vascular complication research.

• Tofacitinib Repairs Inflammation and Mitochondrial Dysfuncti

  2026-05-20

  This study demonstrates that tofacitinib (CP-690550) uniquely reverses both inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. The findings clarify mechanisms of JAK/STAT pathway blockade in models refractory to TNF, IL-6, or metabolic-targeted therapies, with significant implications for immune modulation research.

• Indomethacin in Applied Inflammation and Lipid Metabolism Re

  2026-05-20

  Indomethacin’s unique dual roles as a Cox-1 inhibitor and PPARγ agonist make it indispensable for dissecting inflammation and lipid metabolism in preclinical models. Learn how to optimize workflows, troubleshoot common pitfalls, and translate mechanistic insights—anchored by the latest FXR-KLF11 axis research—using APExBIO’s high-purity Indomethacin (A8449).

• Berberine Counters Estrogen Deficiency Bone Loss via Tuft Ce

  2026-05-19

  The referenced study reveals that berberine counters estrogen deficiency-induced bone loss by stimulating intestinal tuft cell expansion through a butyrate-mediated mechanism. These findings introduce a novel gut-bone axis pathway, establishing a mechanistic rationale for berberine's osteoprotective effects and highlighting translational research opportunities in postmenopausal osteoporosis.

• Bismuth Subsalicylate (A8382): Reliable Solutions in Cell As

  2026-05-19

  This article delivers scenario-driven guidance for biomedical researchers seeking reproducible outcomes in cell viability, proliferation, or cytotoxicity assays. Leveraging practical lab scenarios, we demonstrate how Bismuth Subsalicylate (SKU A8382) from APExBIO addresses common workflow and data interpretation challenges with evidence-backed reliability.

• Dabigatran Etexilate: Clinical Advances in Oral Thrombin Inh

  2026-05-18

  The reference paper establishes dabigatran etexilate as the first clinically approved oral direct thrombin inhibitor, addressing critical limitations of traditional anticoagulants for venous thromboembolism and atrial fibrillation. Its predictable pharmacokinetics, oral bioavailability, and reduced monitoring requirements represent significant progress in anticoagulant therapy and research.

• Carbapenemase Gene Transmission in CREC: Insights from Guang

  2026-05-18

  This study provides a detailed molecular analysis of carbapenemase-encoding gene (CEG) carriage and transfer dynamics in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals in Guangdong, China, during the COVID-19 pandemic. The findings reveal high prevalence and transferability of plasmid-borne blaNDM-1, with significant multidrug resistance implications for clinical and laboratory research.

• PP 1 in Immuno-Oncology: Src Family Kinase Inhibition for Tr

  2026-05-17

  Explore how PP 1, a potent Src family tyrosine kinase inhibitor, enables next-generation cancer and immunology research by dissecting signaling pathways with nanomolar precision. This article uniquely bridges molecular pharmacology with AI-driven biomarker advances for translational impact.

• APOL1 Evolution, Splice Isoforms, and APOL3 Interactions in

  2026-05-16

  This study advances understanding of APOL1's evolutionary adaptation, its splice isoforms, and interactions with APOL3, providing new mechanistic insights into trypanosome resistance and renal cell injury. The findings clarify how specific APOL1 genetic variants and isoforms contribute to both innate immunity and kidney disease risk.

• Cell Counting Kit-8 (CCK-8): Precision Tools for Ferroptosis

  2026-05-15

  Explore how Cell Counting Kit-8 (CCK-8) revolutionizes cell proliferation and cytotoxicity assays—particularly in studies of ferroptosis and iron metabolism. This article uniquely connects recent glioblastoma research with advanced assay optimization.

• Eicosapentaenoic Acid (EPA): Mechanistic Insights and Assay

  2026-05-15

  Explore the multifaceted role of Eicosapentaenoic Acid (EPA) as an omega-3 fatty acid in cardiovascular disease research, emphasizing advanced mechanisms and assay decision-making. This article uniquely integrates mechanistic depth and recent breakthroughs for scientists seeking high-impact research tools.

474 records 12/32 page Previous Next First page 上5页 1112131415 下5页 Last page